SLC25A5 and hepatocellular carcinoma: Combined with previous studies ,we found that SLC25A5 (ANT2), a natural sense transcript of SLC25A5‐AS1, could suppress tumour growth and down‐regulate miR‐19a through the PI3K/AKT pathway in hepatocellular carcinoma cells.11 To determine whether SLC25A5‐AS1 could interact with miR‐19a, we found one potential binding site between miR‐19a‐3p and SLC25A5‐AS1 by miRanda (Figure 5A).